CardiaTec Bio

CardiaTec Bio is at the forefront of biotechnology research, dedicated to decoding cardiovascular disease biology to pioneer novel therapeutic discoveries. Leveraging human heart multiomics data and advanced computational modeling, CardiaTec is committed to developing first-in-class cardiovascular therapies with clear and efficient pathways to clinical translation.

Driven by a robust global network of 65 hospitals, CardiaTec Bio is building the largest proprietary human cardiac multiomics dataset. This extensive dataset is enriched with detailed clinical annotations, enabling the company to unlock groundbreaking insights into the complex biology of cardiovascular diseases. CardiaTec's innovative approach promises to transform the landscape of precision cardiovascular medicine.

CardiaTec Bio, headquartered in Cambridge, GB, is redefining the discovery and development of precision cardiovascular therapies. We invite the management of CardiaTec Bio to create a customized and exclusive company showcase and product listing on our platform, further enhancing their visibility and commercial potential.